Table 3.

Pathologic characteristics of annexin A2 expression in sera of 115 hepatocellular carcinoma patients (mean ±SD)

Group		n	(ng/mL)	t	P value	Pos. (%) > 18 ng/mL	χ2	P value
Sex	Male	88	24.56 ± 5.84	0.150	0.881	78 (88.64)	0.933	0.334
	Female	27	24.79 ± 5.33			22 (81.48)
Age (yr)	≥ 50	87	24.84 ± 6.07	0.798	0.427	76 (87.36)	0.050	0.822
	< 50	28	23.83 ± 4.56			24 (85.71)
Tumor size (cm)	≥ 5.0	75	24.38 ± 5.68	0.850	0.397	66 (88.00)	0.207	0.649
	< 5.0	40	25.35 ± 5.95			34 (85.00)
α-fetoprotein (ng/mL)	≥ 400	53	24.91 ± 5.52	0.531	0.596	45 (84.91)	0.365	0.546
	< 400	62	24.34 ± 5.96			55 (88.71)
HBsAg	Positive	79	27.38 ± 5.67	6.820	< 0.001	73 (92.41)	6.605	0.010
	Negative	36	18.58 ± 7.83			27 (75.00)
Differentiated grading	Well	37	20.43 ± 4.97			25 (67.57)
	Moderate	43	26.19 ± 5.34	4.9661	< 0.0011	41 (95.35)	10.6311	0.0011
	Poor	35	27.05 ± 5.13	5.5611	< 0.0011	34 (97.14)	10.6331	0.0011
TNM staging	Stages I-II	52	21.16 ± 5.97			38 (71.43)
	Stages III-IV	63	27.44 ± 6.01	5.5942	< 0.0012	62 (97.06)	16.1222	< 0.0012
Extrahepatic metastasis	With	62	26.11 ± 5.43	3.191	0.002	58 (93.55)	5.514	0.023
	Without	53	22.79 ± 5.64			42 (79.25)
Portal vein thrombus	With	60	26.03 ± 5.99	2.859	0.005	56 (93.33)	4.498	0.034
	Without	55	23.06 ± 5.03			44 (80.00)

¹Compared with the well differentiated group;

²Compared with the tumor node metastasis (TNM) stage I -II group. HBsAg: Surface antigen of the hepatitis B virus; Pos. (%): Positive case number (%).